| ²é¿´: 1146 | »Ø¸´: 8 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
| ¡¾Óн±½»Á÷¡¿»ý¼«»Ø¸´±¾Ìû×Ó£¬²ÎÓë½»Á÷£¬¾ÍÓлú»á·ÖµÃ×÷Õß rio24 µÄ 5 ¸ö½ð±Ò | |||
rio24½ð³æ (СÓÐÃûÆø)
|
[½»Á÷]
10¸ö½ð±ÒÇóÖú££°¢Ë¾Æ¥ÁÖÒýÆð賦µÀ³öѪµÄÔÒò
|
||
|
Ò»µÀ¿¼Ì⣬·ÖÖµ±È½Ï´ó ³¤ÆÚ·þÓð¢Ë¾Æ¥ÁÖÓÐʱ»áÒýÆð賦µÀ³öѪ£¬ÎªÊ²Ã´£¿ Ï£ÍûÓдóÏÀÄÜÏêϸ½â´ð£¬Ð»Ð» |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÌåÖÆÄÚ³¤±²ËµÌåÖÆÄÚ¾ø´ó²¿·ÖÒ»±²×ÓÔڵײ㣬ÈçͬÄãÃÇÒ»Ñù´ó²¿·ÖÆÕͨ½ÌʦæÇÒÊÕÈëµÍ
ÒѾÓÐ13È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ11È˻ظ´
ΪʲôÖйú´óѧ¹¤¿Æ½ÌÊÚÃÇË®ÁËÄÇô¶àËùνµÄ¶¥»á¶¥¿¯£¬µ«»¹ÊÇ×ö²»³öÓîÊ÷»úÆ÷ÈË£¿
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ5È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ9È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
anyetang
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3720
- ºì»¨: 1
- Ìû×Ó: 762
- ÔÚÏß: 28.5Сʱ
- ³æºÅ: 273982
- ×¢²á: 2006-08-26
- ÐÔ±ð: MM
- רҵ: ҩѧ
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
karl2100(½ð±Ò+1,VIP+0):¶àлÌṩ£¡
rio24(½ð±Ò+5,VIP+0):лл½â´ð¡«£¡
karl2100(½ð±Ò+1,VIP+0):¶àлÌṩ£¡
rio24(½ð±Ò+5,VIP+0):лл½â´ð¡«£¡
| °¢Ë¾Æ¥ÁÖÊÇÒ»¸ö½âÈÈÕòÍ´¿¹Ñ×Ò©,Æä×÷ÓûúÖÆÊÇÒÖÖÆÌåÄÚǰÁÐÏÙËØ£¨PG£©ºÏ³É£¬PGÊÇÌåÄÚÉúÎï»îÐÔºÜÇ¿¡¢ºÜ¹ãµÄÎïÖÊ¡£ÆäÖÐPGE2¾ßÓÐÖÂÈÈ¡¢ÖÂÑס¢ÖÂÍ´¡¢±£»¤Î¸ð¤Ä¤µÈ×÷Óá£PGE2ÄÜ·ÀÖ¹Óк¦Òò×ÓËðÉËθճĤ£¬ÄÜÔ¤·À»¯Ñ§´Ì¼¤ÒýÆðµÄθճĤ³öѪ¡¢ÃÓÀÃÓ뻵ËÀ£¬·¢»Óϸ°û»òճĤ±£»¤×÷Óᣳ¤ÆÚʹÓð¢Ë¾Æ¥ÁÖ£¬ÓÉÓÚÒÖÖÆÁËǰÁÐÏÙËØºÏ³Éø£¨COX¡ª1£©£¬¸ÉÈÅPGS(Ö÷ҪΪPGE2)ºÏ³É£¬Ê¹PGE2Éú³É¼õÉÙ£¬Î¸ð¤Ä¤µÄÆÁÕÏ×÷ÓüõÈõ£¬´Ì¼¤Î¸Õ³Ä¤£¬ÒýÆðÉϸ¹²¿²»ÊÊ£¬Î¸×ÆÍ´£¬ÉõÖÁÓÕ·¢»ò¼ÓÖØÀ£ÑñºÍ³öѪ¡£ |
2Â¥2007-12-22 02:17:47
×ÔÓÉÓã187
ľ³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3473
- Ìû×Ó: 42
- ÔÚÏß: 12.5Сʱ
- ³æºÅ: 465407
- ×¢²á: 2007-11-22
- רҵ: ÖÐҩѧ
3Â¥2007-12-22 08:50:24
Acode
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1677.6
- Ìû×Ó: 77
- ÔÚÏß: 10.6Сʱ
- ³æºÅ: 36203
- ×¢²á: 2004-02-08
- ÐÔ±ð: GG
- רҵ: ÉúÎïÓëҽѧͳ¼ÆÑ§
¡ï
karl2100(½ð±Ò+1,VIP+0):лл£¡
karl2100(½ð±Ò+1,VIP+0):лл£¡
|
¸öÈËÈÏΪ»¹ÓÐÒ»¸öÔÒò£¬¾ÍÊǰ¢Ë¾Æ¥ÁÖÒÖÖÆÄýѪ¶ñÍ飨TXA2£©µÄÐγɣ¬´Ó¶ø¿¹Äý¡£ ÒòΪTXA2ͬPGEΪͬÀàÎïÖÊ£¬Ò²Êܵ½»·¼ÓÑõøµ÷½Ú¡£ |
4Â¥2007-12-22 17:35:25
ºÄ×ÓÅÂè
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 731.3
- Ìû×Ó: 297
- ÔÚÏß: 2.1Сʱ
- ³æºÅ: 439221
- ×¢²á: 2007-10-09
- ÐÔ±ð: MM
- רҵ: Ò©Îï·ÖÎö
5Â¥2007-12-22 19:04:12
sai00fuji
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1049.4
- É¢½ð: 673
- ºì»¨: 3
- Ìû×Ó: 504
- ÔÚÏß: 130.4Сʱ
- ³æºÅ: 470099
- ×¢²á: 2007-11-29
- רҵ: ÉúÎﻯѧ
¡ï
karl2100(½ð±Ò+1,VIP+0):лл·¢ÑÔ£¡
karl2100(½ð±Ò+1,VIP+0):лл·¢ÑÔ£¡
| °¢Ë¾Æ¥ÁÖÓëÆäËû½âÈÈ¿¹Ñ×Ò©²»Í¬£¬Ëü²»¿ÉÄæµÄÒÖÖÆcox£¬Ê¹ÄÚÔ´ÐÔPG£¨ÍâÔ´ÐÔµÄÊÇÖÁÑ×ÎïÖÊ£¬ÄÚÔ´ÐԵĿÉÒÔ±£»¤Î¸Õ³Ä¤£©¼õÉÙ¡£ |
6Â¥2008-01-01 13:54:18
liurong1116
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 89
- Ìû×Ó: 36
- ÔÚÏß: 4.4Сʱ
- ³æºÅ: 335993
- ×¢²á: 2007-03-31
- ÐÔ±ð: MM
- רҵ: Ò©ÀíѧÆäËû¿ÆÑ§ÎÊÌâ
| Ö÷ÒªÔÒòÓÐÕâÑù¼¸µã£ºµÚÒ»¡¢·ÇÑ¡ÔñÐÔµÄÒÖÖÆÁË»·Ñõ»¯Ã¸µÄÁ½ÖÖͬ¹¤Ã¸£¬COX¡ª1ÒÖÖÆ½µµÍÁ˶ÔθճĤµÄ±£»¤£»»¹ÓÐÒ»¸öÔÒò£¬°¢Ë¾Æ¥ÁÖ×ÔÉí¶ÔθճĤϸ°û´æÔÚËðÉË£¬°¢Ë¾Æ¥ÁÖÊÇÈõËáÐÔµÄÒ©ÎÔÚθÄÚµÄËáÐÔ»·¾³ÖÐÒ©ÎïÊǷǽâÀë״̬£¬ÕâʱÈÝÒ×͸¹ýθճĤϸ°ûĤ½øÈëϸ°ûÄÚ£¬¶øÏ¸°ûÄÚÊÇÈõ¼îÐԵĻ·¾³£¬ÄÇôÈõËáÐÔµÄÒ©Îï·Ö½â³ÉΪ½âÀë״̬£¬ÕâÑù¾Í²»ÈÝÒ×ÔÚ´Ë͸¹ý°ûĤ³öϸ°û£¬Òò´Ë»áÔÚϸ°ûÄÚ´óÁ¿¶Ñ»ý£¬¶ÔθճĤÔì³ÉËðÉË¡£ |
7Â¥2008-01-22 23:19:41
fxzxp
Ìú¸Ëľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 11 (СѧÉú)
- ½ð±Ò: 6591.8
- ºì»¨: 3
- Ìû×Ó: 192
- ÔÚÏß: 77.3Сʱ
- ³æºÅ: 53555
- ×¢²á: 2004-09-18
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡ï
karl2100(½ð±Ò+1,VIP+0):¶àлÌṩ£¡
karl2100(½ð±Ò+1,VIP+0):¶àлÌṩ£¡
|
½¨Òé¿´¿´ÏÂÃæÕâ±¾Êé°É¡£ Aspirin_and_Related_Drugs Contents 2 THE INDUSTRIAL HISTORY OF ANALGESICS: THE EVOLUTION OF ANALGESICS AND ANTIPYRETICS J.R. McTavish Recognition of Pain Therapeutic Nihilism and Fevers The Organic Chemical Industry The Salicylates The Value of a Good Name Conclusion References 4 PHARMACOKINETICS AND METABOLISM OF THE SALICYLATES G.G. Graham, M.S. Roberts, R.O. Day and K.D. Rainsford Introduction Absorption of Aspirin and Salicylate Distribution of Aspirin and Salicylate Elimination of Aspirin Elimination of Salicylate Metabolic Pathways of Salicylate Factors Controlling the Elimination of Aspirin and Salicylate Kinetics of Elimination of Salicylate Pro-Drugs Analytical Methods for the Salicylates Salicylate Derivatives Diflunisal Salicylamide References 5 METABOLISM AND PHARMACOKINETICS OF IBUPROFEN G.G. Graham and K.M. Williams Introduction Absorption Distribution Elimination Half-life and Clearance Factors Affecting the Elimination of Ibuprofen Pharmacokinetics, Plasma Concentrations and Clinical Response Analytical Methods References 6 PHARMACOKINETICS AND METABOLISM OF PARACETAMOL (ACETAMINOPHEN) G.G. Graham and M. Hicks Introduction Absorption Distribution © 2004 K.D. Rainsford Elimination Half-life and Clearance Factors Affecting the Elimination of Paracetamol Metabolism of Pro-drugs Analytical Methods References 7 PHARMACOLOGY AND BIOCHEMISTRY OF SALICYLATES AND RELATED DRUGS K.D. Rainsford Introduction Anti-inflammatory Effects Biochemical Effects of Salicylates in Relation to their Anti-inflammatory Actions Analgesic Activity Antipyresis References Appendix to Chapter 7 8 SIDE EFFECTS AND TOXICOLOGY OF THE SALICYLATES K.D. Rainsford Introduction Occurrence of Adverse Events from NSAIDs, including Aspirin Gastrointestinal Side Effects Hepatotoxicity Nephropathy Hypersensitivity Reactions and Asthma Teratogenesis and Pregnancy Miscellaneous Side Effects Acute Salicylate Poisoning Conclusions References 9 REYE¡¯S SYNDROME AND ASPIRIN J.F.T. Glasgow and S.M. Hall Introduction Background Definition Clinical Features Investigations © 2004 K.D. Rainsford Differential Diagnosis Aetiology and Pathogenesis Management Principles The Future Conclusion Acknowledgements References 10 SALICYLATES IN THE TREATMENT OF ACUTE PAIN K.D. Rainsford Introduction Concepts of the Mode of Action in Acute Pain Early Observations in Various Pain States Efficacy in Various Pain Conditions Comparative Effects in Acute Pain States References 11 ACETYLSALICYLIC ACID FOR THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASES K.E. Webert and J.G. Kelton The Role of Platelets in Haemostasis and Thrombosis The Role of Platelets in Acute and Chronic Vascular Injury Effects of Acetylsalicylic Acid on Platelet Function Pharmacokinetics of ASA Dose¨CEffect Relationships of ASA The Effects of ASA on Coagulation Factors, other than Platelets ASA for the Prevention of Vascular Thromboembolic Disease: Epidemiological Studies ASA for the Treatment of Acute Vascular Thromboembolic Events Novel Analogues of Salicylates and Further Developments References 12 USE OF SALICYLATES IN RHEUMATIC AND RELATED CONDITIONS W.W. Buchanan, W.F. Kean and K.D. Rainsford Introduction History Rheumatoid Arthritis Osteoarthritis Miscellaneous musculoskeletal disorders Drug Kinetics and Monitoring © 2004 K.D. Rainsford Adverse Events in Rheumatic Patients Factors Affecting Side Effects and Therapeutic Effects Toxicity Conclusions References . 13 ASPIRIN AND NSAIDs IN THE PREVENTION OF CANCER, ALZHEIMER¡¯S DISEASE AND OTHER NOVEL THERAPEUTIC ACTIONS K.D. Rainsford Introduction Prevention of Colorectal and Other Cancers Alzheimer¡¯s Disease and Related Dementias Copper Salicylates in the Treatment of Inflammatory Diseases and Cancer Therapeutic Uses of Aspirin in Pregnancy Kawasaki Disease Perturbed Metabolic States Immunological Effects Other Possible Uses Miscellaneous References ¸½¼þ´«²»ÉÏÀ´£¡ http://rapidshare.de/files/18302639/Aspirin.rar.html http://rapidshare.com/files/1138 ... Drugs-KINGDWARF.zip [ Last edited by fxzxp on 2008-1-23 at 10:08 ] |
8Â¥2008-01-23 10:02:16
ÒÒõ£Ë®ÑîËá
ľ³æ (ÕýʽдÊÖ)
KOP
- Ó¦Öú: 9 (Ó×¶ùÔ°)
- ½ð±Ò: 3359
- É¢½ð: 26
- ºì»¨: 3
- Ìû×Ó: 515
- ÔÚÏß: 359.4Сʱ
- ³æºÅ: 504616
- ×¢²á: 2008-02-16
- ÐÔ±ð: GG
- רҵ: ÌìȻҩÎﻯѧ
°¢Ë¾Æ¥ÁÖ
¡ï
karl2100(½ð±Ò+1,VIP+0):¶àлÌṩ£¡
karl2100(½ð±Ò+1,VIP+0):¶àлÌṩ£¡
| °¢Ë¾Æ¥ÁÖ±¾ÉíΪˮÑîËáõ¥½á¹¹£¬ËäÈ»õ¥»¯ÁË·ÓôÇ»ù£¬µ«ÈÔÈ»´ø1¸öÓÎÀëµÄôÈ»ù£¬¶Ô賦µÀ¾ßÓд̼¤×÷Ó㬴ËÍⰢ˾ƥÁÖ×÷Ϊ1ÖÖ½âÈÈÕòÍ´Ò©Æä»úÀíΪÒÖÖÆ»·ÑõºÏø¼õÉÙǰÁÐÏÙËØPGµÄ²úÉú£¬¶øPGÖ÷ÒªÓб£»¤Î¸ð¤Ä¤µÄ×÷ÓÃÒò´Ë°¢Ë¾Æ¥ÁÖÈÝÒ×ÒýÆð賦µÀ³öѪ |

9Â¥2008-02-17 10:44:39













»Ø¸´´ËÂ¥